Report Pursuant to Section 28a of the Danish Securities Trading Act


Copenhagen, Denmark; December 9, 2010 - Pursuant to Section 28a of the Danish   
Securities Trading Act, Genmab A/S (OMX: GEN) shall make public information on  
transactions by managerial employees and their related parties involving Genmab 
shares and related instruments, as follows:                                     

Name:	Jan G. J. van de Winkel                                                   
Reason: President & Chief Executive Officer                                     
Issuer: Genmab A/S                                                              
ID code/ ISIN: DK0010272202                                                     
Description: Warrants                                                           
Transaction: Grant                                                              
Trading date: December 9, 2010                                                  
Market: NASDAQ OMX Copenhagen A/S                                               
Number: 50,000                                                                  
Value: DKK 1,864,500                                                            

Name:	David A. Eatwell                                                          
Reason: Executive Vice President & Chief Financial Officer                      
Issuer: Genmab A/S                                                              
ID code/ ISIN: DK0010272202                                                     
Description: Warrants                                                           
Transaction: Grant                                                              
Trading date: December 9, 2010                                                  
Market: NASDAQ OMX Copenhagen A/S                                               
Number: 35,000                                                                  
Value: DKK 1,305,150                                                            

The exercise price for each warrant is DKK 66.60. Each warrant entitles the     
owner to subscribe one share of nominally DKK 1. On the basis of an exercise    
price of DKK 66.60 and by application of the Black-Scholes formula, the average 
value of each warrant can be calculated as DKK 37.29 based on an interest rate  
of 1.8948% and the historical volatility of Genmab A/S shares calculated at     
64.15%.                                                                         

About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for the potential treatment of cancer.        
Genmab's world class discovery and development teams are using cutting-edge     
technology to create and develop products to address unmet medical needs.  Our  
primary goal is to improve the lives of patients who are in urgent need of new  
treatment options.  For more information on Genmab's products and technology,   
visit www.genmab.com.                                                           

Contact:                                                                        
Helle Husted, Vice President, Investor Relations                                
T: +45 33 44 77 30, M: +45 25 27 47 13, E: h.husted@genmab.com                  

This Stock Exchange Release contains forward looking statements. The words      
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions  
identify forward looking statements. Actual results or performance may differ   
materially from any future results or performance expressed or implied by such  
statements. The important factors that could cause our actual results or        
performance to differ materially include, among others, risks associated with   
product discovery and development, uncertainties related to the outcome and     
conduct of clinical trials including unforeseen safety issues, uncertainties    
related to product manufacturing, the lack of market acceptance of our products,
our inability to manage growth, the competitive environment in relation to our  
business area and markets, our inability to attract and retain suitably         
qualified personnel, the unenforceability or lack of protection of our patents  
and proprietary rights, our relationships with affiliated entities, changes and 
developments in technology which may render our products obsolete, and other    
factors. For a further discussion of these risks, please refer to the section   
“Risk Management” in Genmab's Annual Report, which is available on              
www.genmab.com.  Genmab does not undertake any obligation to update or revise   
forward looking statements in this Stock Exchange Release nor to confirm such   
statements in relation to actual results, unless required by law.               

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM);
HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-TF(TM);     
HuMax-Her2(TM); HuMax-Wnt(TM); HuMax-cMet(TM) and UniBody(R) are all trademarks 
of Genmab A/S. Arzerra(R) is a trademark of GlaxoSmithKline.                    

Stock Exchange Release no. 47

Attachments

47_warrant_grant_section_28a_091210_uk.pdf
GlobeNewswire

Recommended Reading